Le Lézard
Classified in: Health, Covid-19 virus
Subjects: CHI, WOM, FDA

Dr. David Berger of Tampa to Address Pregnancy Safety Concerns with FDA COVID-19 Vaccine Advisory Committee


TAMPA, Fla., Feb. 25, 2021 /PRNewswire/ -- According to Pew Research Center, women of childbearing age in the United States have greater hesitancy about the COVID-19 vaccines compared to men. A contributing factor is likely the lack of data available regarding the effect of COVID-19 vaccines on pregnant women or their offspring, especially as it relates to DNA-containing vaccines like the one Johnson & Johnson is requesting the FDA approve this week.

On February 26, 2021, the FDA Vaccines and Related Biological Products Advisory Committee will meet to discuss Emergency Use Authorization (EUA) of the Johnson & Johnson/Jansenn Biotech COVID-19 Vaccine.   Dr. David Berger will give a presentation regarding continued vaccine hesitancy and safety concerns related to pregnancy and the COVID-19 vaccines (see submitted slide presentation and submitted written comments).

Dr. David Berger, founder and medical director of Wholistic Pediatrics & Family Care in Tampa, Florida, is a Board Certified pediatrician with decades of experience specializing in preconception, pregnancy, and infant and childhood health. He also serves as Senior Medical Advisor of the Vaccine Considerations Project. He previously addressed the committee during their EUA meeting regarding Pfizer on December 10th and Moderna on December 17th. 

Dr. Berger has specific concerns about the Johnson & Johnson COVID-19 vaccine for women of childbearing age.

We know the mRNA-based Pfizer and Moderna vaccines do not enter the nucleus of the cell, so they cannot come into contact with human DNA. At this time, we cannot confidently say the same for the Johnson & Johnson COVID-19 vaccine and this may have safety implications for developing fetuses.  - David Berger, MD, FAAP

Although pregnant women and those trying to conceive want pregnancies free of COVID-19 medical complications, they also often want to minimize synthetic chemicals from entering their bodies.

"Researchers are not certain that genetic material from this type of vaccine will not cause issues for pregnant women or developing fetuses," said Dr. Berger. "For women to be able to make informed decisions, it is critical the scientific community better determine if the various COVID-19 vaccines have differing impacts on a developing fetus."

Dr. Berger intends to tell the FDA that, until more is known, mRNA vaccines such as Pfizer and Moderna may be better options for women of childbearing age who are choosing to get a COVID-19 vaccine.

Dr. Berger will present to the Committee between 1:10 pm - 2:10 pm ET on Thursday, February 26, 2021. The online meeting can be viewed at:

FDA Webcast

YouTube

Dr. Berger also produced a series of YouTube videos on COVID-19 topics important to his patients, and social media campaigns to notify the public about FDA vaccine approval meetings.

Dr. Berger is available for further public comment before or after his committee presentation.

Media Contact Information:
Whitley Procopio
[email protected] 
c: (727) 902-0748

SOURCE Wholistic Pediatrics & Family Care


These press releases may also interest you

at 00:25
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial...

28 mar 2024
The "Global Clinical In Vitro Diagnostic Medical Laboratory Services Market: Strategy & Trends with Volume & Price Forecasts by Chemistry, Hematology, Microbiology, Pathology, Covid-19, and Molecular Dx by Country. Updated with Impact of COVID-19"...

28 mar 2024
Discovery Silver Corp. ("Discovery" or the "Company") today announced financial results for the three and twelve months ended December 31, 2023 ("Q4 2023" and "2023", respectively). The Company also provided a summary of key events since the...

28 mar 2024
The "Molecular Diagnostics at the Point of Care. By Application, Technology, Place, Product and by Country. With Executive Guides and Customization 2023 - 2027 " report has been added to  ResearchAndMarkets.com's offering. Infectious disease Dx is...

28 mar 2024
The "Whole Genome and Exome Sequencing Markets by Application, Organism and Product with Executive and Consultant Guides. Includes Direct to Consumer Analysis. 2023 to 2027" report has been added to  ResearchAndMarkets.com's offering. Will all...

28 mar 2024
Boat Rocker Media Inc. ("Boat Rocker" or the "Company") , an independent, integrated global entertainment company, today reported its financial results for the three months ended December 31, 2023 ("fourth quarter" or "Q4") and for the year ended...



News published on and distributed by: